|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For multiple myeloma (MM), B-cell maturation antigen (BCMA) has been recently proved to be a promising target.
|
31847470 |
2019 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we conducted the clinical trial of a biepitope-targeting CAR T against B cell maturation antigen (BCMA) (LCAR-B38M) in 17 R/R MM cases.CAR T cells were i.v. infused after lymphodepleting chemotherapy.
|
30988175 |
2019 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
T-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma.
|
1396583 |
1992 |
|
T-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The BCMA gene is a new gene discovered by the molecular analysis of a t(4;16) translocation, characteristic of a human T cell lymphoma.
|
9846698 |
1998 |
|
T-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In a previous study of a t(4;16)(q26;p13) translocation, found in a human malignant T-cell lymphoma the BCMA gene, located on chromosome band 16p13.1, has been characterized.
|
8165126 |
1994 |
|
Ulcerative Colitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the haplotypes of the TNFRSF17 polymorphisms might be associated with UC and IBS susceptibility.
|
20016944 |
2010 |
|
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to investigate whether the polymorphisms in the TNFRSF17 gene are associated with susceptibility to colorectal cancer (CRC).
|
22108903 |
2012 |
|
Gastrointestinal Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Identification of single nucleotide polymorphisms in the TNFRSF17 gene and their association with gastrointestinal disorders.
|
20016944 |
2010 |
|
Inflammatory Bowel Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We previously found that the haplotypes of TNFRSF17 single nucleotide polymorphisms (SNPs) were associated with the susceptibility to inflammatory bowel disease on Korean population.
|
22108903 |
2012 |
|
Irritable Bowel Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the haplotypes of the TNFRSF17 polymorphisms might be associated with UC and IBS susceptibility.
|
20016944 |
2010 |
|
Osteoarthritis, Knee
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this randomized, open-label, parallel, active controlled clinical study, 139 patients with knee OA were randomly assigned to receive either a curcumin 500-mg (BCM-95<sup>®</sup>) capsule three times daily or a diclofenac 50-mg tablet two times daily for 28 days.
|
30975196 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate the potential clinical utility of PLGA nanotechnology-based cancer vaccine to enhance BCMA-targeted immunotherapy against myeloma.
|
31427721 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B-cell maturation antigen (BCMA) is expressed by normal and malignant plasma cells and is targeted via anti-BCMA chimeric antigen receptor T-cell therapy (BCMA CAR T-cell therapy) in plasma cell myeloma (PCM) patients.
|
30053652 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data corroborate BCMA is a suitable target in B cell tumors beyond MM, providing a novel therapeutic option for patients where BCMA is expressed at low abundance or where anti-CD19 immunotherapies have failed due to antigen loss.
|
30078440 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell maturation antigen (BCMA) has recently been identified as an important multiple myeloma (MM)-specific target for chimeric antigen receptor (CAR) T cell therapy.
|
29678657 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood CAR-BCMA T cells were predominantly highly differentiated CD8<sup>+</sup> T cells 6 to 9 days after infusion.BCMA antigen loss from MM was observed.
|
29812997 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a proof-of-concept study to demonstrate that ultra-small (<5 nm) gadolinium-containing nanoparticles bound to full-length antibodies against the B-cell maturation antigen (BCMA) exhibit rapid tumor uptake followed by renal clearance, improving the signal-to-noise ratio for MM detection beyond levels that are currently afforded by other FDA-approved clinical imaging modalities.
|
31650133 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA produced unprecedented results in heavily pretreated relapsed and/or refractory MM.
|
31780814 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results demonstrate that circulating BCMA levels in most RRMM patients are high enough to interfere with anti-BCMA antibody binding to MM tumor cells and may interfere with BCMA-targeted immune-based therapies.
|
31035033 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCMA is also solubilized in the blood (soluble BCMA [sBCMA]) and MM patients with progressive disease have significantly higher sBCMA levels than those responding to treatment. sBCMA circulating in the blood may limit the efficacy of these anti-BCMA-directed therapies.
|
29230672 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
|
26960399 |
2016 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Now, advances are being made using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, and kappa-light chain as well as CD19 on putative myeloma stem cells.
|
28233151 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
|
31434693 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.
|
31042825 |
2019 |